Pharmafile Logo

Rare Disease Day 2021

February 22, 2021 |  

To mark Rare Disease Day 2021 on Sunday 28 February, OPEN Health will be intentionally quiet on all LinkedIn channels from 26 February to 1 March in order not to distract from awareness generated by patient groups.

To mark Rare Disease Day 2021 on Sunday 28 February, OPEN Health will be intentionally quiet on all LinkedIn channels from 26 February to 1 March in order not to distract from awareness generated by patient groups.

In fact, we want to offer our platform to amplify the voices of the rare disease community and we will be sharing Rare Disease Day-related content during this period. So, if you are part of a patient group and would like us to share your posts, please tag #Share4Rare and we will happily share to our network.

We recognise the importance of this day for rare disease patient groups in supporting their communities and raising awareness, and it’s for this reason that OPEN Health is saying “Shhhh” on Rare Disease Day 2021!

If you would like to understand more about our commitment, capabilities and experience in rare disease please contact:

Gavin Jones, Global Advisor, Rare Diseases

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

OPEN Health announces a new team of experts will lead its HEOR & Market Access Scientific Office

OPEN Health, a global provider of consultancy, HEOR and market access, and scientific communications services, announced a new team of experts will lead its HEOR & Market Access Scientific Office.

OPEN Health Appoints Richard Jones as President for Evidence & Access

OPEN Health is pleased to announce the appointment of Richard Jones as President for Evidence & Access.

Drive, Discover, Dive_OPEN Health

Learn how to unlock the power of simplicity in complex omnichannel healthcare communications.

Novel Oncology Therapies Require Innovative Methods in Oncology Modeling

Innovative methods in oncology modeling are needed to demonstrate the value of many new cancer treatments, including immuno-oncologic therapies.

The CM Group rebrands to OPEN Health

Following its acquisition by OPEN Health in 2022, The CM Group, a US healthcare agency offering a suite of solutions to the biotech and pharma industry, has undergone extensive rebranding...

OPEN Health to acquire leading US-based life science strategy and advisory firm Acsel Health

OPEN Health to acquire leading US-based life science strategy and advisory firm Acsel Health

OPEN Health Appoints David P. King as Non-Executive Chairman and Paul Carter as Independent Board Member

OPEN Health has announced additions to its board of directors, appointing David P. King as non-executive Chairman and Paul Carter as an independent board member.

Steve Chick joins OPEN Health as Chief Growth Officer for Evidence & Access

OPEN Health is pleased to announce the appointment of Stephen J. Chick as Chief Growth Officer for OPEN Health Evidence & Access.

OPEN Health to acquire leading US medical communications platform The CM Group from NaviMed Capital

OPEN Health, a pre-eminent global provider of scientific communications and market access services, announced that it signed a binding agreement to acquire The CM Group, a leading US domestic medical...

How digital health is changing the relationship between patients and health providers | OPEN Health

The pandemic has forced pharmaceutical industry to look at digital in a new way - and it’s driving better health outcomes